Literature DB >> 19762363

Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis.

Valerie P Nell-Duxneuner1, Tanja A Stamm, Klaus P Machold, Stephan Pflugbeil, Daniel Aletaha, Josef S Smolen.   

Abstract

OBJECTIVE: Specific composite indices assessing disease activity in psoriatic arthritis (PsA) have not yet been sufficiently validated. The objective of this study was to identify instruments best reflecting disease activity in PsA.
METHODS: Measures for inclusion in clinical trials, as recommended by the OMERACT-7/8 PsA workshops, were assessed. A principal component analysis (PCA) was performed with cross-sectional data of 105 patients with PsA to identify a minimal set of important dimensions for a disease activity assessment tool for PsA. This was compared with components contained in existing composite indices.
RESULTS: The PCA revealed four principal components best reflecting disease activity. The first contained patient global and pain assessment; the second contained 66/68 swollen and tender joint counts as main variables; C-reactive protein (CRP) best loaded to the third component; and the fourth was loaded by skin assessment but did not reach significance. When comparing the three significant principal components with items of established composite measures, they were best covered by the Disease Activity Index for Reactive Arthritis (DAREA) which comprises patient pain and global assessments, 66/68 joint counts and CRP.
CONCLUSION: Among the currently available indices used in arthritic conditions, the DAREA best reflects the domains found to be important in PsA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19762363     DOI: 10.1136/ard.2009.117945

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

Review 1.  Ultrasound in psoriatic arthritis. Can it facilitate a best routine practice in the diagnosis and management of psoriatic arthritis?

Authors:  Marwin Gutierrez; Antonella Draghessi; Chiara Bertolazzi; Gian Luca Erre; Lina Maria Saldarriaga-Rivera; Alberto López-Reyes; Javier Fernández-Torres; Marcelo J Audisio; Carlos Pineda
Journal:  Clin Rheumatol       Date:  2015-08-23       Impact factor: 2.980

Review 2.  Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.

Authors:  Aizad Mumtaz; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

3.  Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.

Authors:  Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Merih Birlik; Fatoş Önen
Journal:  Rheumatol Int       Date:  2018-09-08       Impact factor: 2.631

Review 4.  Patient-Reported Outcomes in Psoriatic Arthritis.

Authors:  Ana-Maria Orbai; Alexis Ogdie
Journal:  Rheum Dis Clin North Am       Date:  2016-03-16       Impact factor: 2.670

5.  Spondyloarthritis: Which composite measures to use in psoriatic arthritis?

Authors:  Raffaele Scarpa; Francesco Caso
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

6.  The effects of golimumab on work productivity and quality of life among work-active axial spondyloarthritis and psoriatic arthritis patients treated in the routine care in Greece: the 'GO-UP' study.

Authors:  Panagiotis Athanassiou; Anastasios Kotrotsios; Ioannis Kallitsakis; Andreas Bounas; Theodoros Dimitroulas; Alexandros Garyfallos; Maria G Tektonidou; Giorgos Vosvotekas; Achilleas Livieratos; Evangelia Petrikkou; Gkikas Katsifis
Journal:  Qual Life Res       Date:  2021-11-28       Impact factor: 4.147

7.  Development of a Composite Outcome Measure for Systemic Sclerosis Related Interstitial Lung Disease.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Ning Li; Daniel E Furst; Philip J Clements; Robert M Elashoff
Journal:  Rheumatology (Sunnyvale)       Date:  2015-06-30

Review 8.  Treat-to-target in spondyloarthritis: implications for clinical trial designs.

Authors:  James Cheng-Chung Wei
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 9.  Advances in the management of psoriatic arthritis.

Authors:  Ignazio Olivieri; Salvatore D'Angelo; Carlo Palazzi; Angela Padula
Journal:  Nat Rev Rheumatol       Date:  2014-07-08       Impact factor: 20.543

Review 10.  Patient involvement in outcome measures for psoriatic arthritis.

Authors:  William Tillett; Ade Adebajo; Mel Brooke; Willemina Campbell; Laura C Coates; Oliver FitzGerald; Laure Gossec; Philip Helliwell; Sarah Hewlett; Jana James; Patricia Minnock; Aisling Reast; Dennis O'Sullivan; Maarten de Wit; Neil McHugh
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.